During iDR25 – the international drug repurposing conference organized by Remedi4all – RARE-NL is prominently represented. In various sessions, we share our insights and experiences on the reuse of existing medicines for new indications (drug repurposing).

On Thursday, May 8, Evert Manders will take part in a session focused on exploring initiatives that improve patient access to repurposed treatments. He will present his research into alternative pricing models for these medicines – models that, on the one hand, fairly reflect the efforts and costs involved in further development, and on the other, ensure affordability for healthcare systems. Using the real-world example of bevacizumab, a cancer drug used off-label for wet macular degeneration, he will explore what a newly registered formulation of this medicine could reasonably cost, based on past and required investments.

With this contribution, RARE-NL demonstrates how innovative financial and policy solutions can help create a more sustainable and accessible landscape for drug repurposing.